COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series

COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series

Objective To assess the safety, immunogenicity and cellular responses following the Moderna Spikevax primary series in rheumatic disease.Methods We conducted a 12-month, prospective, non-randomised, open-label, comparative trial of adults with either rheumatoid arthritis (RA, n=131) on stable treatm...

Full description

Bibliographic Details
Main Authors: Emmanouil Rampakakis, Paul R Fortin, Sasha Bernatsky, Louis Bessette, Ines Colmegna, Elizabeth Hazel, Laëtitia Michou, Mary-Ann Fitzcharles, Louis Flamand, Emmanuelle Rollet-Labelle, Marc-André Langlois, Valeria Valerio, Nathalie Amiable, Mariana Useche, Deirdre McCormack, Pantelis Panopalis
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/9/4/e003400.full

Internet

https://rmdopen.bmj.com/content/9/4/e003400.full

Similar Items